Výsledky vyhledávání - "V J Spanswick"

Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients

Autor: A Jonson, V J Spanswick, R. Bulusu, J Shaw, R Sehmbi, John A. Hartley, A Mayer, Ian A. Cree, Pippa Corrie

Publikováno v: British Journal of Cancer

Gemcitabine and treosulfan are DNA-damaging agents. Preclinical studies suggest that synergism exists when melanoma cells are exposed to both drugs concurrently. We conducted a phase I trial in advanced melanoma patients to determine the optimal dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79e15f7eaafc2718b337e31067ea96ca
http://europepmc.org/articles/PMC2361787

Zobrazit plný text záznamu

The Autoxidation of the Reduced Forms of EO9

Autor: V J Spanswick, John Butler, Jeffrey Cummings

Publikováno v: Free Radical Research. 25:141-148

The properties of the semiquinone radical from [3-hydroxy-5-aziridinyl-1-methyl-2-(1H-indole-4,7-indi one)-prop-beta-en-alpha-ol], EO9, have been studied using pulse-radiolysis techniques. The reduction potential of the semiquinone of EO9 at pH7.4, E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29b50f5620e4fb1cdeb7bb40c2b2c88c
https://doi.org/10.3109/10715769609149919

Zobrazit plný text záznamu

Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay

Autor: V J, Spanswick, J M, Hartley, T H, Ward, J A, Hartley

Publikováno v: Methods in molecular medicine. 28

DNA damaging agents have been widely used in cancer chemotherapy for many years and have proved successful in the treatment of both solid tissue and haematological malignancies. Many commonly used clinical agents, such as members of the nitrogen must

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e6f91cdbf58b4d3cfd9ba8d3368c609e
https://pubmed.ncbi.nlm.nih.gov/21374035

Zobrazit plný text záznamu

Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells

Autor: R G, Wickremasinghe, K, Ganeshaguru, D T, Jones, C, Lindsay, V J, Spanswick, J A, Hartley, M, Wadhwa, R, Thorpe, A V, Hoffbrand, H G, Prentice, A B, Mehta

Publikováno v: British journal of haematology. 114(3)

We have studied the actions of autologous plasma on both basal and DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia (B-CLL) cells. Apoptosis was quantified using morphological criteria and Western blot analysis for the apoptosis-specif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d23a2422f5a7a833dfa83787ad043f22
https://pubmed.ncbi.nlm.nih.gov/11552986

Zobrazit plný text záznamu

Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay

Autor: J M, Hartley, V J, Spanswick, M, Gander, G, Giacomini, J, Whelan, R L, Souhami, J A, Hartley

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 5(3)

The single cell gel electrophoresis comet assay has become established as a sensitive technique for measuring DNA strand breaks. The technique has been modified to allow the sensitive detection and quantitation of DNA interstrand cross-linking at the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a53227521bd6f2be3f4ba401f7cbf11f
https://pubmed.ncbi.nlm.nih.gov/10100700

Zobrazit plný text záznamu

Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development

Autor: J, Cummings, V J, Spanswick, M, Tomasz, J F, Smyth

Publikováno v: Biochemical pharmacology. 56(4)

Mitomycin C (MMC) is the prototype bioreductive DNA alkylating agent. To exploit its unique properties and maximize patient responses, different therapeutic approaches have been investigated. Recently, the focus has concentrated on monitoring the lev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d592bf185af243404fc62ea08facbcbf
https://pubmed.ncbi.nlm.nih.gov/9763215

Zobrazit plný text záznamu

281 Investigation of the effect of the sequence-selective DNA cross-linking agent SJG-136 on canine tumour cells in vitro

Autor: David E. Thurston, A J Stell, V J Spanswick, M Mellinas-Gomez, S J Baines, John A. Hartley

Publikováno v: European Journal of Cancer Supplements. 8:91

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7eb6d1d7227e585e164018c565b73e57
https://doi.org/10.1016/s1359-6349(10)71988-1

Zobrazit plný text záznamu

Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule

Autor: I. Puzanov, W. Lee, J. D. Berlin, M. W. Calcutt, D. L. Hachey, W. L. Vermeulen, V. J. Spanswick, J. A. Hartley, A. P. Chen, M. L. Rothenberg

Publikováno v: Journal of Clinical Oncology. 26:2504-2504

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b145b2bff8aef2815f20e007bf4a4105
https://doi.org/10.1200/jco.2008.26.15_suppl.2504

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání